[13] [9] Patients should report any changes in symptoms, particularly neurological manifestations, as these may indicate inadequate dosing or alternative diagnoses
Beyond weight loss, early exploratory data suggest potential benefits including: Reductions in HbA1c (a marker of blood sugar control) in people with type 2 diabetes Improvements in lipid profiles (cholesterol and triglycerides) Reductions in liver fat, which may be relevant for metabolic dysfunction-associated steatotic liver disease (MASLD, formerly NAFLD), though these findings are preliminary Possible cardiovascular benefits
My recommendation The mere lack of research into the safety of BPC-157 means that I wont take it for either sport or medical reasons the difference between useful and harmful often lies in getting the dosage right, and at this stage were flying blind
Search authorised UK medicines Human Medicines Regulations 2012, Regulation 279
The GI side effects are present but manageable